SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). On February 17, 2017, Momenta announced that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration. The Company’s Abbreviated New Drug Application (ANDA) for its Glatopa 40 mg product candidate is still under regulatory review, with final approval reliant upon the acceptable resolution of the compliance observations at the Pfizer manufacturing facility. In an earnings call on February 21, 2017, Momenta President and CEO Craig Wheeler stated that, as a result of the warning letter, “it is unlikely that Sandoz’s ANDA for Glatopa 40 mg will be approved in the first quarter of 2017.” To obtain additional information, go to:

http://zlk.9nl.com/momenta-mnta

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.